Proton pump inhibitor for non-erosive reflux disease: A meta-analysis

Table 1 Details of these studies n (%)

First author	Country	Year	Study design	Arms of treatment	Age (yr)	Gender (M/F)	n	BMI	Helicobacter pylori infection	Hiatal hernia	Smokers	Alcohol users	Therapeutic duration	Adverse events	Effective
Talley	United	2002	RCT	Esomeprazole 20 mg	48.0	135/158	293	-	90	89	-	-	6 mo	5	101 (34.6)
et al[23]	Kingdom			Esomeprazole 40 mg	48.4	135/147	282	-	101	92	-	-		6	84 (29.7)
				placebo	48.2	58/88	146	-	57	39	-	-		2	30 (17.8)
Juul-Hansen	Norway	2009	RCT	Lansoprazole 15 mg	47.5	11/21	32	26.4	6	10	8	-	6 mo	2	28 (87.5)
et al[24]				Ranitidine 75 mg	48.0	12/19	31	25.2	6	6	8	-		4	14 (45.2)
Kinoshita	Japan	2011	RCT	Rabeprazole 5 mg	46.3	38/55	93	22.4	35	-	-	-	4 wk	32	36 (35.0)
et al[25]				Rabeprazole 10 mg	46.8	50/51	101	23.2	42	-	-	-		37	44 (44.0)
				placebo	49.7	40/51	91	23.2	44	-	-	-		32	19 (21.0)
Kobeissy	Lebanon	2012	RCT	Rabeprazole 20 mg	45.4	16/28	44	-	-	-	-	-	4 wk	-	20 (45.5)
et al[26]				Ranitidine 300 mg	45.1	16/23	39	-	-	-	-	-		-	17 (43.6)
Talley	Australia	2001	RCT	Esomeprazole 20 mg	49.0	94/76	170	-	64	65	-	-	6 mo	11	146 (85.0)
et al[27]				placebo	49.0	98/74	172	-	57	75	-	-		13	83 (48.0)
Fass	United States	2009	RCT	Dexlansoprazole 30 mg	47.6	84/231	315	29.0	95	-	72	162	4 wk	6	173 (54.9)
et al[28]				Dexlansoprazole 60 mg	47.5	106/209	315	29.6	90	-	57	181		8	157 (50.0)
				placebo	47.6	84/233	317	29.1	89	-	52	182		1	59 (18.5)
Fujiwara	Japan	2005	RCT	Omeprazole 20 mg	55.0	20/30	50	22.8	22	14	6	18	4 wk	-	43 (86.0)
et al[29]				Famotidine 20 mg	56.6	23/25	48	22.2	22	11	11	17		-	36 (75.0)
Nakamura	Japan	2010	RCT	Omeprazole 20 mg	51.4	8/9	17	-	5	9	-	-	8 wk	0	13 (75.0)
et al[30]				Roxitidine 75 mg	48.6	9/7	16	-	7	8	-	-		0	11 (70.6)
Miner	United States	2002	RCT	Rabeprazole 10 mg	44.4	28/37	65	30.9	17	-	22	29	4 wk	14	19 (29.3)
et al[31]				Rabeprazole 20 mg	45.5	25/33	68	30.3	24	-	21	26		17	19 (28.3)
				placebo	46.1	24/26	70	30.2	28	-	22	30		18	2 (3.4)
Armstrong	Canada	2001	RCT	Pantoprazole 40 mg	47.1	57/49	106	-	16	-	66	71	4 wk	32	41 (52.8)
et al[32]				Nizatidine 150 mg	47.6	51/51	102	-	20	-	64	67		39	33 (42.9)
Lind	Sweden	1999	RCT	Omeprazole 10 mg	52.0	53/86	139	-	-	76	24	88	4 wk	-	116 (83.5)
et al[33]				Omeprazole 20 mg	51.0	65/77	142	-	-	72	43	85		-	99 (69.7)
				placebo	48.0	61/82	143	-	-	74	57	97		-	80 (55.9)
Richter	United States	2000	RCT	Lansoprazole 15 mg	44.9	115/161	276	-	66	-	75	132	8 wk	-	37 (13.4)
et al[34]				Lansoprazole 30 mg	45.1	122/155	277	-	66	-	88	129		-	97 (35.0)
				Ranitidine 150 mg	45.2	108/170	278	-	63	-	69	126		-	64 (23.0)
				placebo	46.3	30/37	67	-	9	-	19	35		-	10 (14.7)
Bytzer	Denmark	2004	RCT	Rabeprazole 10 mg	47.0	123/156	279	26.0	100	-	-	-	6 mo	113	241 (86.4)
et al[12]				placebo	48.0	57/82	139	27.0	52	-	-	-		47	94 (67.6)
Kahrilas	United States	2009	RCT	Rabeprazole 20 mg	43.1	40/89	129	29.3	42	-	35	58	4 wk	-	42 (32.4)
et al[35]				placebo	44.0	45/87	132	30.0	40	-	36	51		-	5 (3.8)
Lind	Sweden	1997	RCT	Omeprazole 10 mg	49.0	89/110	199	-	-	-	60	133	4 wk	6	98 (49.2)
et al[33]				Omeprazole 20 mg	50.0	66/139	205	-	-	-	46	121		11	125 (61.0)
				placebo	51.0	51/54	105	-	-	-	22	64		7	25 (23.8)
Uemura	Japan	2008	RCT	Omeprazole 10 mg	44.4	47/49	96	-	37	5	-	-	4 wk	12	44 (45.8)
et al[36]				Omeprazole 20 mg	43.8	53/40	93	-	49	9	-	-		22	43 (46.2)
				placebo	42.4	53/49	92	-	32	2	-	-		17	22 (23.9)
Talley	Australia	2002	RCT	Pantoprazole 20 mg	53.0	78/76	154	28.9	-	-	65	28	6 mo	86	109 (71.0)
et al[27]				Ranitidine 150 mg	52.0	83/70	153	28.4	-	-	61	30		83	86 (56.0)

RCT: Randomized controlled trials; M: Male; F: Female; BMI: Body mass index.